Recently, two novel therapeutic classes have emerged: sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists
If patients are looking at a $499-or-higher price tag, you might as well say it costs a million dollars a month, because theyre not going to access it. The ad features a New Yorker -styled comic strip, in which two employees at the Department of Health and Human Services (HHS) are holding a lengthy High-Priced Drug List. It would have been quicker to make a low-priced drug list, the punchline quips
B., Milligan, G
More than 1,000 participants took part in this trial, and the results were striking: 10,800 FU/day of nattokinase (not the traditionally recommended 2,000 FU) produced meaningful improvements across cardiovascular markers, including lipids, carotid intima-media thickness, and plaque size
The company's core revenue stream comes from consumer subscriptions to its mobile app, which combines AI-powered content delivery with human coaching to drive behavior change
In receptor-based analyses, the GLP-1 pathway is primarily examined in relation to the regulation of glucose-dependent insulin secretion, the inhibition of glucagon signalling, and mechanisms involved in appetite control